International Battery
International Battery Metals Ltd.
  • International Battery Metals (IBAT) has closed a follow up private placement financing for gross proceeds of CAD$6,693,500 (USD$5,000,000)
  • The company will use the new funds for working capital needs as it accepts pre-placement orders for new DLE processing plants
  • It will also use the funds to narrow prospective customer lithium brine resource locations to those sites most conducive for volume production
  • International Battery Metals is a Vancouver-based advanced direct lithium extraction technology company
  • International Battery Metals Ltd. (IBAT) opened trading at C$1.16 per share

International Battery Metals (IBAT) has closed a follow up private placement financing for gross proceeds of CAD$6,693,500 (USD$5,000,000).

This follow up private placement is being made by the group who invested CAD$10,000,000 in February, 2022.

The company will use the new funds for working capital needs as it accepts pre-placement orders for new DLE processing plants. It will also use the funds to narrow prospective customer lithium brine resource locations to those sites most conducive for volume production.

About the company

International Battery Metals is a Vancouver-based advanced direct lithium extraction technology company. It focuses on ethical and ecological extraction of lithium from brines.

The company is applying its patented intellectual property into building mobile lithium extraction units that can be utilized worldwide. The revolutionary lithium extraction technology is defined by its extreme environmental and resource protection, rapid implementation and production, and low capital and operating costs.

International Battery Metals Ltd. (IBAT) opened trading at C$1.16 per share.

The materials provided in this article are for information only and should not be treated as investment advice. For full disclaimer information, please click here.

More From The Market Online
(Source: VitalHub Corp.)

VitalHub acquires MedCurrent Corp. for $12M

VitalHub (TSX:VHI) has closed its acquisition of MedCurrent Corp. in an all-cash transaction for C$12.0 million.
Medical technician looking into a microscope

Theralase’s bladder cancer drug under investigation in clinical study

Pharma stock Theralase Technologies (TSXV:TLT) announces a significant update on its ongoing bladder cancer clinical study.